Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the current call. The company has repaid all existing debt excluding the term loan for the Jammu project. The Jammu project is funded partly by a Rs. 235 crore project loan at 6% interest subvention. IPO proceeds of Rs. 293 crores are being deployed as planned over two years; about Rs. 62 crores planned for FY25. No indication of fresh equity or debt raising beyond the existing Jammu project loan and IPO proceeds utilization. Capex plans include another Rs. 100 crore investment in the Jammu facility during the year. Overall, the

Any current/future capex/capital investment/strategic investment?

Ongoing capital work in progress is primarily for the Jammu project, with around Rs. 330 crore invested so far. Total anticipated project cost for Jammu facility is approximately Rs. 450 crore, with an expected additional Rs. 100 crore investment in coming quarters. Commercial production at Jammu is planned to start in Q2 FY25. Normal maintenance CAPEX for existing operations is estimated around Rs. 5-7 crores per annum. Future investments aim to enhance capacity, including three more blocks at Jammu and expansion of Cephalosporin block. The company expects to utilize IPO proceeds as planned a

Future growth expectations in sales/revenue/volumes?

The company expects a strong growth in CDMO business, targeting 20%+ CAGR in the coming year, driven by new capacity from Jammu facility and increased utilization of existing facilities. Volume growth in CDMO is projected at 10%+ annually; revenue growth depends on price stability or increase. With the Jammu facility coming online, acute segment sales are expected to increase, boosting overall revenue. Gross margins expected to stabilize around 25%-26%, with improved margins from Jammu due to GST benefits. EBITDA growth is linked to volume growth rather than top-line revenue, with a 10% increa

Future growth expectations in earnings/operating earnings/profits/EPS?

Innova Captab is optimistic about 20%+ CAGR growth in the near term driven by: - Expansion and commissioning of the new Jammu facility with state-of-the-art automation. - Volume growth in CDMO business expected at 10%+ despite price erosion. - EBITDA growth supported by volume increases and GST benefits from Jammu facility. FY24 EBITDA grew by 35.9% to Rs. 166.9 crores; PAT grew 38.9% to Rs. 94.3 crores YoY. EBITDA margin expected to remain around 25% ± 2-3% with potential improvement from GST benefits. The company expects revenue from Jammu facility to exceed Rs. 1,000 crore over 3-4 ye

Current/ Expected Orderbook/ Pending Orders?

The company is in advanced discussions for commercial production at its Jammu facility, expecting revenue ramp-up 4-5 months after starting. Current visibility on new inquiries and orders is positive, especially with existing customers and new product SKUs. The existing facilities at Baddi have spare capacity, particularly in the General block (40%-45% utilization), while Cephalosporin block is heavily utilized (~70%). The company is aiming to increase wallet share with existing customers and onboard new customers. Jammu facility investments (~Rs. 100-120 crores) are expected to add capacity a

Innova CaptabQ4 FY24Pharmaceuticals & Biotechnology

Innova Captab Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,168P/E: 47.6Market Cap: ₹7.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company expects a strong growth in CDMO business, targeting 20%+ CAGR in the coming year, driven by new capacity from Jammu facility and increased utilization of existing facilities.
Volume growth in CDMO is projected at 10%+ annually; revenue growth depends on price stability or increase.
With the Jammu facility coming online, acute segment sales are expected to increase, boosting overall revenue.
Gross margins expected to stabilize around 25%-26%, with improved margins from Jammu due to GST benefits.
EBITDA growth is linked to volume growth rather than top-line revenue, with a 10% increase in standalone EBITDA reported.
Export business and branded generics are also focused growth areas alongside CDMO.
New inquiries and customer onboarding for Jammu facility are in advanced stages, expected to convert into revenue within 4-5 months post commercial production start.

Margin guidance

Category 2

Innova Captab is optimistic about 20%+ CAGR growth in the near term driven by:
- Expansion and commissioning of the new Jammu facility with state-of-the-art automation.
- Volume growth in CDMO business expected at 10%+ despite price erosion.
- EBITDA growth supported by volume increases and GST benefits from Jammu facility.
FY24 EBITDA grew by 35.9% to Rs. 166.9 crores; PAT grew 38.9% to Rs. 94.3 crores YoY.
EBITDA margin expected to remain around 25% ± 2-3% with potential improvement from GST benefits.
The company expects revenue from Jammu facility to exceed Rs. 1,000 crore over 3-4 years.
Sustainable gross margins anticipated around 25%-26%, aided by higher-margin branded and Sharon businesses.
Realignment and integration of acquired Sharon entities expected to support profitability improvement.
Management aims to maintain operational efficiencies, cash generation, and steady maintenance CAPEX (Rs. 5-7 crores per annum).

See what Innova Captab management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No specific mention of new fundraising through debt or equity in the current call.
The company has repaid all existing debt excluding the term loan for the Jammu project.
The Jammu project is funded partly by a Rs. 235 crore project loan at 6% interest subvention.
IPO proceeds of Rs. 293 crores are being deployed as planned over two years; about Rs. 62 crores planned for FY25.
No indication of fresh equity or debt raising beyond the existing Jammu project loan and IPO proceeds utilization.
Capex plans include another Rs. 100 crore investment in the Jammu facility during the year.
Overall, the company appears focused on utilizing current resources and existing loans rather than new fundraising.

Order book

The company is in advanced discussions for commercial production at its Jammu facility, expecting revenue ramp-up 4-5 months after starting.
Current visibility on new inquiries and orders is positive, especially with existing customers and new product SKUs.
The existing facilities at Baddi have spare capacity, particularly in the General block (40%-45% utilization), while Cephalosporin block is heavily utilized (~70%).
The company is aiming to increase wallet share with existing customers and onboard new customers.
Jammu facility investments (~Rs. 100-120 crores) are expected to add capacity and contribute to growth.
With capacity expansions and new facilities, a 20%+ CAGR in the CDMO category is targeted.
The order book appears strong based on customer engagement and capacity ramp-up plans, although exact orderbook numbers are not provided.

See what Innova Captab management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing capital work in progress is primarily for the Jammu project, with around Rs. 330 crore invested so far.
Total anticipated project cost for Jammu facility is approximately Rs. 450 crore, with an expected additional Rs. 100 crore investment in coming quarters.
Commercial production at Jammu is planned to start in Q2 FY25.
Normal maintenance CAPEX for existing operations is estimated around Rs. 5-7 crores per annum.
Future investments aim to enhance capacity, including three more blocks at Jammu and expansion of Cephalosporin block.
The company expects to utilize IPO proceeds as planned and has repaid all existing debt except the project loan for Jammu.
Jammu facility benefits from GST and interest subvention incentives expected to improve margin profile.

Track Innova Captab — get its next earnings analysis in your feed

How does Innova Captab rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisInnova Captab

Rev 2Mar 2

See where Innova Captab sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Innova Captab rank in Pharmaceuticals & Biotechnology?

Compare Innova Captab against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Innova Captab's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Innova Captab Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Innova Captab rank in Pharmaceuticals & Biotechnology?

Continue your research

What Innova Captab's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season